Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.38 |
| ▸ | MAPKAPK3 | Q16644 | 4/20 | 0.38 |
| ▸ | MAPK6 | Q16659 | 4/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.38 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10131378 | 0.84 | ADORA2A (0.46) | ADORA2AADORA2BCYP1A2JAK2MAP2K4 | |
| SCHEMBL12222 | 0.79 | MAP2K4 (0.57) | ADORA2AADORA2BCYP1A2JAK2MAP2K4 | |
| SCHEMBL29769133 | 0.79 | MAP2K4 (0.57) | ADORA2AADORA2BCYP1A2JAK2MAP2K4 | |
| SCHEMBL14404116 | 0.78 | JAK2 (0.60) | JAK2MAPK1GSK3BPDPK1NTRK1 | |
| SCHEMBL24149246 | 0.76 | ADORA2A (0.46) | ADORA2AADORA2BCYP1A2JAK2MAP2K4 | |
| SCHEMBL13122049 | 0.76 | FADS1 (0.49) | ADORA2AADORA2BCYP1A2JAK2 | |
| SCHEMBL23062796 | 0.76 | MAP2K4 (0.53) | ADORA2AADORA2BCYP1A2JAK2MAP2K4 | |
| SCHEMBL8045852 | 0.76 | ITK (0.46) | ADORA2AADORA2BCYP1A2MAP2K4GSK3B | |
| SCHEMBL24610364 | 0.76 | ADORA2A (0.46) | ADORA2AADORA2BCYP1A2JAK2MAP2K4 | |
| SCHEMBL182633 | 0.76 | JAK2 (0.63) | ADORA2AADORA2BCYP1A2JAK2MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016150800-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-29 | — | — | WO | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | MET, DMPK, RET | ADORA2A 4255/4885ADORA2B 4325/4885CYP1A2 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.